Literature DB >> 19100913

mTOR-understanding the clinical effects.

A G Contreras1, O Dormond, M Edelbauer, K Calzadilla, A Hoerning, S Pal, D M Briscoe.   

Abstract

The target of rapamycin (TOR) is a highly conserved serine/threonine kinase that controls cell growth and metabolism in response to nutrients, growth factors, cellular energy, and stress. The TOR kinase, which was originally discovered in yeast, is also expressed in human cells as mammalian TOR (mTOR). In this review, we focus on how mTOR-inducible signals function in cell protection and cell survival of effector and regulatory T cells as well as its role in endothelial cell biology. We evaluate how signaling is important for vascular endothelial cell growth, survival, and proliferation; and we consider how the function of mTOR in endothelial cells may be clinically important in the rejection process. Understanding the biology of mTOR allows clinicians to use mTOR inhibitors optimally as therapeutics following solid organ transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100913      PMCID: PMC3392643          DOI: 10.1016/j.transproceed.2008.10.011

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  28 in total

Review 1.  TOR, a central controller of cell growth.

Authors:  T Schmelzle; M N Hall
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Immunologic targets for currently available immunosuppressive agents: what is the optimal approach for children?

Authors:  M Sho; D V Samsonov; D M Briscoe
Journal:  Semin Nephrol       Date:  2001-09       Impact factor: 5.299

Review 3.  TOR signaling in growth and metabolism.

Authors:  Stephan Wullschleger; Robbie Loewith; Michael N Hall
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

Review 4.  Angiogenesis and endothelial cell repair in renal disease and allograft rejection.

Authors:  Marlies E J Reinders; Ton J Rabelink; David M Briscoe
Journal:  J Am Soc Nephrol       Date:  2006-02-15       Impact factor: 10.121

5.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

Review 6.  Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide.

Authors:  T R Brazelton; R E Morris
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

7.  mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s.

Authors:  Maria A Frias; Carson C Thoreen; Jacob D Jaffe; Wayne Schroder; Tom Sculley; Steven A Carr; David M Sabatini
Journal:  Curr Biol       Date:  2006-08-17       Impact factor: 10.834

8.  Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

Authors:  Thuy L Phung; Keren Ziv; Donnette Dabydeen; Godfred Eyiah-Mensah; Marcela Riveros; Carole Perruzzi; Jingfang Sun; Rita A Monahan-Earley; Ichiro Shiojima; Janice A Nagy; Michelle I Lin; Kenneth Walsh; Ann M Dvorak; David M Briscoe; Michal Neeman; William C Sessa; Harold F Dvorak; Laura E Benjamin
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

9.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

Review 10.  Growing roles for the mTOR pathway.

Authors:  Dos D Sarbassov; Siraj M Ali; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

View more
  10 in total

Review 1.  Chronic allograft rejection: a fresh look.

Authors:  Johannes Wedel; Sarah Bruneau; Nora Kochupurakkal; Leo Boneschansker; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

2.  Constitutive activation of the mTOR signaling pathway within the normal glomerulus.

Authors:  Gearoid M McMahon; Dipak Datta; Sarah Bruneau; Martin Kann; Myda Khalid; Jacqueline Ho; Tatsuichiro Seto; Jordan A Kreidberg; Isaac E Stillman; David M Briscoe
Journal:  Biochem Biophys Res Commun       Date:  2012-07-22       Impact factor: 3.575

Review 3.  Targeting the intragraft microenvironment and the development of chronic allograft rejection.

Authors:  Olivier Dormond; Marc Dufour; Tatsuichiro Seto; Sarah Bruneau; David M Briscoe
Journal:  Hum Immunol       Date:  2012-08-03       Impact factor: 2.850

4.  Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.

Authors:  Kangwu Chen; Jianqiang Mo; Ming Zhou; Genlin Wang; Guizhong Wu; Hao Chen; Kai Zhang; Huilin Yang
Journal:  Med Oncol       Date:  2014-02-18       Impact factor: 3.064

Review 5.  NLRP3 Inflammasome at the Interface of Inflammation, Endothelial Dysfunction, and Type 2 Diabetes.

Authors:  Ilona M Gora; Anna Ciechanowska; Piotr Ladyzynski
Journal:  Cells       Date:  2021-02-03       Impact factor: 6.600

6.  Rapamycin impairs endothelial cell function in human internal thoracic arteries.

Authors:  David C Reineke; Else Müller-Schweinitzer; Bernhard Winkler; Donatina Kunz; Moritz A Konerding; Thomas Grussenmeyer; Thierry P Carrel; Friedrich S Eckstein; Martin T R Grapow
Journal:  Eur J Med Res       Date:  2015-06-24       Impact factor: 2.175

7.  Cord Blood Cells Responses to IL2, IL7 and IL15 Cytokines for mTOR Expression.

Authors:  Anahita Mohammadian; Elahe Naderali; Seyedeh Momeneh Mohammadi; Aliakbar Movasaghpour; Behnaz Valipour; Mohammad Nouri; Hojjatollah Nozad Charoudeh
Journal:  Adv Pharm Bull       Date:  2017-04-13

8.  Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

Authors:  Sean M McBride; Daniel A Perez; Mei-Yin Polley; Scott R Vandenberg; Justin S Smith; Shichun Zheng; Kathleen R Lamborn; John K Wiencke; Susan M Chang; Michael D Prados; Mitchel S Berger; David Stokoe; Daphne A Haas-Kogan
Journal:  J Neurooncol       Date:  2009-08-25       Impact factor: 4.130

9.  Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation.

Authors:  Sarah Bruneau; Craig Bryan Woda; Kevin Patrick Daly; Leonard Boneschansker; Namrata Gargee Jain; Nora Kochupurakkal; Alan Gabriel Contreras; Tatsuichiro Seto; David Michael Briscoe
Journal:  Front Immunol       Date:  2012-04-02       Impact factor: 7.561

Review 10.  The role of everolimus in liver transplantation.

Authors:  Rainer Ganschow; Jörg-Matthias Pollok; Martin Jankofsky; Guido Junge
Journal:  Clin Exp Gastroenterol       Date:  2014-09-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.